Supplementary Figure 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Figure 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

Supplementary Table 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Table 1 from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

Supplementary Figure and Table Legend from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Figure and Table Legend from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

Supplementary Data from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Supplementary Data from Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplati

HERTHENA-Lung02: Phase 3 study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI - supplementary material

infographic</p

LA-NSCLC lymph nodal mediastinal PET positivity–question 9.

LA-NSCLC lymph nodal mediastinal PET positivity–question 9.</p

LA-NSCLC diagnosis with lymph nodal negativity–question 10.

LA-NSCLC diagnosis with lymph nodal negativity–question 10.</p

Additional file 1 of SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

Additional file 1

sj-pdf-1-tmj-10.1177_03008916221099558 – Supplemental material for Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)

Supplemental material, sj-pdf-1-tmj-10.1177_03008916221099558 for Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®) by Caterina Caminiti, Jane Bryce, Silvia Riva, Diane Ng, Francesca Diodati, Elisa Iezzi, Lucia Sparavigna, Silvia Novello, Camillo Porta, Lucia Del Mastro, Giuseppe Procopio, Saverio Cinieri, Amalia Falzetta, Fabio Calabrò, Vito Lorusso, Alessio Aligi Cogoni, Giampaolo Tortora, Marco Maruzzo, Rodolfo Passalacqua, Francesco Cognetti, Vincenzo Adamo, Enrica Capelletto, Alessandra Ferrari, Michela Bagnalasta, Maurizio Bassi, Annalisa Nicelli, Davide De Persis, Alessia D’Acunti, Elisabetta Iannelli (patient), Francesco Perrone and Sandra A. Mitchell in Tumori Journal</p

Features of 421 respondents (AIRO/AIOM/AIPO/SICT) to the survey.

Features of 421 respondents (AIRO/AIOM/AIPO/SICT) to the survey.</p